Good practices shared by European HealthTech Hubs and companies followed by an interactive Q&A sessions. Financial support to demonstrate the proof of concept What to expect from this session? - Support to companies: how VCs, regional/national/European grants, business partners, banks, etc. are supporting the “proof(s) of value” stage for DMDs including the regulatory procedures, clinical investigations, discussion with payers, etc.). How the relationship between entrepreneurs and their financial partners could evolve during that specific period. - Companies: what was their experience regarding the “proof of value” stage for their DMD, for the access to the European market.

Good practices shared by European HealthTech Hubs and companies followed by an interactive Q&A session. How to convince and reach the payers, and the type of payers considered as direct clients (care related entities, private insurances, social security systems, etc.) What to expect from this session ? - Support to companies: some regions have put in place “fast track” programs such as DiHa in Germany, mhealth in Belgium, etc that can of course contribute to a faster adoption of the technology. - Companies: what business model do they have and how did they approach the payers from the European scene, what business model did they consider when approaching the European market.

- Hayley Every | Entrepreneurship Lead | EIT Health Belgium-Netherlands Transforming healthcare in Europe: EIT Health’s support for digital health solutions Europe is facing critical healthcare challenges including infectious diseases, pandemics, antimicrobial resistance, and rising healthcare costs. In response, EIT Health has developed a flagship concept to contribute to the EU's health priorities and build a European Health Union. One of the flagship priorities is focussed on facilitating the uptake of digital medical devices. This presentation will provide an overview of the programmes available within EIT Health to support the adoption of digital health solutions by patients and healthcare systems across Europe. - Andrzej Rys | Director responsible for Health Systems, Medical Products and Innovation | Directorate-General for Health and Food Safety (DG SANTE), European Commission Description to come!

Good practices shared by European HealthTech Hubs and companies followed by an interactive Q&A session. The market access for DMDs sometimes require complex clinical studies. For some DMD companies, it is a real challenge to design a convincing clinical design because of different factors such as the novelty (no gold standard), the lack of interest from the clinical partners, the difficult choice in choosing relevant endpoints, etc. What to expect from this session? - Support to companies: within this session, the dedicated-existing regional/national/European tools in place will be discussed. - Companies: experiences and testimonies of the challenges encountered for the clinical validation of their DMD, and the solutions found/considered.